Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Prediagnostic prescription antibiotics use and survival in patients with colorectal cancer: a swedish national register-based study
Umeå universitet, Medicinska fakulteten, Institutionen för strålningsvetenskaper, Onkologi.ORCID-id: 0000-0003-2517-6881
Umeå universitet, Medicinska fakulteten, Wallenberg centrum för molekylär medicin vid Umeå universitet (WCMM). Umeå universitet, Medicinska fakulteten, Institutionen för kirurgisk och perioperativ vetenskap.ORCID-id: 0000-0002-0974-6373
Umeå universitet, Medicinska fakulteten, Institutionen för strålningsvetenskaper, Onkologi.
Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin.ORCID-id: 0000-0001-6808-4405
Visa övriga samt affilieringar
2023 (Engelska)Ingår i: Cancer Epidemiology, Biomarkers and Prevention, ISSN 1055-9965, E-ISSN 1538-7755, Vol. 32, nr 10, s. 1391-1401Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

BACKGROUND: Antibiotics use is associated with higher colorectal cancer risk, but little is known regarding any potential effects on survival.

METHODS: We conducted a nationwide cohort study, using complete-population data from Swedish national registers between 2005 and 2020, to investigate prediagnostic prescription antibiotics use in relation to survival in colorectal cancer patients.

RESULTS: We identified 36,061 stage I-III and 11,242 stage IV colorectal cancer cases diagnosed between 2010 and 2019. For stage I-III, any antibiotics use (binary yes/no variable) was not associated with overall or cancer-specific survival. Compared with no use, moderate antibiotics use (total 11-60 days) was associated with slightly better cancer-specific survival [adjusted HR (aHR) = 0.93; 95% confidence interval (CI), 0.86-0.99)], whereas very high use (>180 days) was associated with worse survival [overall survival (OS) aHR = 1.42; 95% CI, 1.26-1.60, cancer-specific survival aHR = 1.31; 95% CI, 1.10-1.55]. In analyses by different antibiotic types, although not statistically significant, worse survival outcomes were generally observed across several antibiotics, particularly macrolides and/or lincosamides. In stage IV colorectal cancer, inverse relationships between antibiotics use and survival were noted.

CONCLUSIONS: Overall, our findings do not support any substantial detrimental effects of prediagnostic prescription antibiotics use on cancer-specific survival after colorectal cancer diagnosis, with the possible exception of very high use in stage I-III colorectal cancer. Further investigation is warranted to confirm and understand these results.

IMPACT: Although the study findings require confirmation, physicians probably do not need to factor in prediagnostic prescription antibiotics use in prognosticating patients with colorectal cancer.

Ort, förlag, år, upplaga, sidor
American Association For Cancer Research (AACR), 2023. Vol. 32, nr 10, s. 1391-1401
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
URN: urn:nbn:se:umu:diva-215390DOI: 10.1158/1055-9965.EPI-23-0340PubMedID: 37490284Scopus ID: 2-s2.0-85173563887OAI: oai:DiVA.org:umu-215390DiVA, id: diva2:1807800
Forskningsfinansiär
Cancerforskningsfonden i Norrland, LP17–2154Cancerforskningsfonden i Norrland, LP21-2275Region Västerbotten, RV-932777Tillgänglig från: 2023-10-27 Skapad: 2023-10-27 Senast uppdaterad: 2024-02-20Bibliografiskt granskad
Ingår i avhandling
1. Antibiotics use in relation to colorectal cancer risk, survival and postoperative complications
Öppna denna publikation i ny flik eller fönster >>Antibiotics use in relation to colorectal cancer risk, survival and postoperative complications
2024 (Engelska)Doktorsavhandling, sammanläggning (Övrigt vetenskapligt)
Abstract [en]

Background: Growing evidence suggests that antibiotic-induced dysbiosis of gut microbiota potentially contributes to colorectal cancer development and oncological outcomes. However, the role of antibiotics in colorectal cancer incidence, survival and postoperative outcomes at a population level remains incompletely understood.

Aims: The overall aim of the thesis is to investigate prescription antibiotics use in relation to colorectal cancer risk, survival and postoperative complications, particularly surgical site infections including anastomotic leakage.

Methods: The thesis work includes matched case-control and cohort studies, leveraging complete population-based data from Swedish national registers. Paper I is a matched case-control study that consists of 40 545 colorectal cancer cases and 202 720 matched controls, aiming to investigate antibiotics use and risk of incident colorectal cancer. Multivariable conditional logistic regression was used. Paper II is a cohort study, including 47 303 colorectal cancer cases, investigating antibiotics use in relation to cancer-specific survival. Stratified Cox proportional-hazards regression was used. Paper III includes 38 839 colorectal cancer cases who had undergone abdominal tumour-resection surgery and assesses antibiotics use in relation to surgical site infections, including anastomotic leakage, within 30 days after surgery. Logistic regression with multi-level mixed-effects models was used.

Results: In paper I, a dose-response association between antibiotics use and a higher risk of proximal colon cancer was found, whereas a slight inverse association with rectal cancer was observed, mainly in women. A null association was found between methenamine hippurate, assessed as a negative control due to no known effect on gut microbiome, and the risk of colorectal cancer. In paper II, the findings did not support any substantial negative effect of antibiotics on cancer-specific survival, except for very high cumulative exposure (>180 days) in stage I-III diseases. In stage IV colorectal cancer, modest inverse relationships between antibiotics use and survival were noted. In paper III, prescription antibiotics use up to 4.5 years before surgery was associated with a higher risk of surgical site infections, including anastomotic leakage, after colon cancer surgery but not rectal cancer surgery. A null association was observed between methanamine hippurate and the risk of surgical site infections. For cardiovascular and/or neurological complications, also considered as a negative control due to expected negligible or null effects of gut microbiome on these outcomes after surgery, associations were null in both colon and rectal cancer.

Conclusion: These studies provided further support for antibiotics use as a modifiable risk factor for proximal colon cancer and identified antibiotics taken long before surgery as a novel risk factor for surgical site infections, including anastomotic leakage, after colon cancer surgery. In contrast, we did not find any substantial negative impact of antibiotics on cancer-specific survival. Taken together, the findings described in this thesis provide etiological insights and may contribute to strategies to prevent colon cancer and improve postoperative outcomes through prudent use of antibiotics, thereby aiding in the reduction of colorectal cancer incidence and mortality.

Ort, förlag, år, upplaga, sidor
Umeå: Umeå University, 2024. s. 64
Serie
Umeå University medical dissertations, ISSN 0346-6612 ; 2282
Nyckelord
colorectal cancer, antibiotics, gut microbiome, dysbiosis, cancer-specific survival, surgical site infections, anastomotic leakage, register-based epidemiology
Nationell ämneskategori
Cancer och onkologi
Forskningsämne
cancerepidemiologi; cancerepidemiologi; onkologi; kirurgi
Identifikatorer
urn:nbn:se:umu:diva-221316 (URN)978-91-8070-270-6 (ISBN)978-91-8070-271-3 (ISBN)
Disputation
2024-03-22, Hörsal Betula, 6M Building, Umeå University Hospital, Umeå, 13:00 (Engelska)
Opponent
Handledare
Tillgänglig från: 2024-03-01 Skapad: 2024-02-20 Senast uppdaterad: 2024-02-21Bibliografiskt granskad

Open Access i DiVA

fulltext(1540 kB)72 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 1540 kBChecksumma SHA-512
e9d49d0847266457e279838d6c2bf9f03d7a0f94cc748281b9d039cefe8834e923997347b17cb7321b6d85b6adaa0a6d925f1ae29dcada868f671699ab4fb241
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Lu, Sai San MoonRutegård, MartinHäggström, ChristelGylfe, ÅsaHarlid, Sophiavan Guelpen, Bethany

Sök vidare i DiVA

Av författaren/redaktören
Lu, Sai San MoonRutegård, MartinHäggström, ChristelGylfe, ÅsaHarlid, Sophiavan Guelpen, Bethany
Av organisationen
OnkologiWallenberg centrum för molekylär medicin vid Umeå universitet (WCMM)Institutionen för kirurgisk och perioperativ vetenskapInstitutionen för folkhälsa och klinisk medicinInstitutionen för klinisk mikrobiologiUmeå Centre for Microbial Research (UCMR)Molekylär Infektionsmedicin, Sverige (MIMS)
I samma tidskrift
Cancer Epidemiology, Biomarkers and Prevention
Cancer och onkologi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 72 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 185 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf